Definium Therapeutics reported success in the first of two planned Phase 3 trials of its orally dosed LSD-based therapy for generalized anxiety disorder. The company said the treatment significantly eased anxiety symptoms in the randomized study, following a separate Phase 3 win in major depression reported earlier. In the Phase 3 generalized anxiety disorder trial, 214 patients received a single dose of DT120 or placebo. Definium framed the result as a clean clinical readout supporting continued development, with the second Phase 3 study still ongoing. The sequential Phase 3 momentum positions the program for greater commercial and regulatory attention, particularly in a field where evidence durability and tolerability drive differentiation between psychoactive candidates. For investors and clinicians, the timing is critical: two Phase 3 datasets can shape the strength of any registrational package. The data also intensifies scrutiny of safety monitoring for psychedelic-derived therapies as programs advance, even when efficacy endpoints land favorably.